A Study to Evaluate the Safety and Clinical Efficacy of STR-P004

Summary

This study is a single-arm, single-center, open-label, multiple-dose, dose-escalation early clinical study aimed at evaluating the safety, tolerability, and pharmacokinetic profile of STR-P004 in subjects with relapsed/refractory CD19-positive B-cell non-Hodgkin lymphoma, and preliminarily observing its antitumor activity.

Timeline

Start

2025-06

Primary completion

2026-04

Completion

2027-05

Drugs

Indications